Hengrui Medicine Releases 2026 "Quality Improvement, Efficiency Enhancement, and Return on Investment" Action Plan, Focusing on Innovation and Internationalization

Log in to Sina Finance App and search for [Information Disclosure] to see more evaluation levels

Zhongfang Network Data  Jiangsu Hengrui Medicine Co., Ltd. released the 2026 “Quality Improvement, Efficiency Enhancement, and Return” action plan on March 25, and summarized the implementation results of the 2025 plan. In 2025, the company achieved operating revenue of 31.63B yuan, a year-on-year increase of 13.02%; net profit attributable to the parent was 7.71B yuan, a year-on-year increase of 21.69%. Sales revenue of innovative drugs reached 16.34B yuan, a year-on-year increase of 26.09%, with the proportion of drug sales revenue rising to 58.34%. External licensing income became a new growth engine, with revenue recognized during the reporting period of 3.39B yuan. R&D investment remained high, with a total of 8.72B yuan in 2025, including 6.96B yuan in expense-based investments. In 2025, the company had 7 Class 1 innovative drugs and 1 Class 2 new drug approved for listing, and submitted 15 applications for innovative drugs/new indications.

Looking toward 2026, Hengrui Medicine will continue to focus on the two major strategies of “technological innovation” and “internationalization,” concentrating on core therapeutic areas such as tumors, metabolism and cardiovascular diseases, immune and respiratory system diseases, and neuroscience, to build a differentiated innovation product matrix. The company plans to leverage leading technology platforms like HRMAP and HOT-Ig to accelerate the development of potential blockbuster products, and continue to promote globalization through external licensing and autonomous overseas clinical trials to unlock product potential. Regarding investor returns, the company has formulated profit distribution and mid-year dividend plans for 2025 and 2026, and is advancing a share repurchase plan of 1 to 2 billion yuan. As of February 28, 2026, approximately 698 million yuan has been repurchased and paid. The company commits to holding no fewer than 3 performance briefing sessions in 2026, strengthening information disclosure and investor communication, and continuously evaluating and improving the “Quality Improvement, Efficiency Enhancement, and Return” action plan.